Clinical Trial Results: Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a combination of oxaliplatin, Xeloda (capecitabine), and cetuximab for first-line treatment of metastatic or unresectable gastric or ga…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• OXALIPLATIN (Oxaliplatin)
• Xeloda (capecitabine)

Snippet

Sponsor: University of Southern California | Conditions: Gastric Cancer, Esophageal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2026-07-30